Glaucoma News and Research

Latest Glaucoma News and Research

Allergan reports operating results for the third quarter of 2009

Allergan, Inc. today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

29 Oct 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Pan-American Association of Ophthalmology (PAAO) Joint Meeting, includes a Veterans Administration study that indicates that Iraq and Afghanistan veterans with vision loss from traumatic brain injury have significantly poorer quality of life than comparable civilian patients, and a Harvard doctor's insights on how to best evaluate and care for low-vision patients who experience vivid visual hallucinations due to Charles Bonnet syndrome.

28 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO).

27 Oct 2009

STAAR Surgical Company reports promising assessments from CAST

STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products today reported that the Collamer Accommodating Study Team (CAST) formed by the company in late 2008 has provided very promising initial patient vision assessments from the first phase of the project.

26 Oct 2009

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic.

26 Oct 2009

Saving sight in premature babies: The past, present and future of ROP treatment

26 Oct 2009

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

The ARVO Foundation for Eye Research (AFER) and Pfizer Ophthalmics are pleased to announce a series of awards named in honor of Carl B. Camras, MD. Up to three awards of $10,000 each will be presented annually for a period of 10 years to early career researchers.

24 Oct 2009

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants’ proposed generic products until the last to expire of the infringed patents, which is 2022.

24 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

ISTA Pharmaceuticals, Inc. today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.

22 Oct 2009

VisionGraft Sterile Cornea allograft now available at Tissue Banks International

Tissue Banks International (TBI) has announced the availability of the VisionGraft Sterile Cornea, the nation's first sterile cornea allograft. The VisionGraft Sterile Cornea (patent pending) is an irradiated cornea for use in tectonic transplant procedures.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

Electronic eye implant mimics human retina; restores partial vision

A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision. A team led by Dr. Lucian V. Del Priore at NewYork-Presbyterian Hospital/Columbia University Medical Center performed the June 26 surgery -- the first case of its kind in New York.

22 Oct 2009

Gloomy health care statistics in Texas top state news

New outlets report on a variety of health issues at the state level including gloomy health statistics and the rising cost of premiums for sick workers in Texas, a Medicaid program that could provide a model for national health care reform in North Carolina and Medicaid cuts in Michigan.

19 Oct 2009

Lexicon Pharmaceuticals completes public offering of common stock shares

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering of shares of its common stock. The offering included an aggregate of 38,333,332 shares of Lexicon's common stock after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

15 Oct 2009

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc., announced today preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina.

8 Oct 2009

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Glaucoma News and Research

Latest Glaucoma News and Research

Allergan reports operating results for the third quarter of 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

STAAR Surgical Company reports promising assessments from CAST

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Saving sight in premature babies: The past, present and future of ROP treatment

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Shire announces new pharmacokinetic data of ADHD medication

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve

VisionGraft Sterile Cornea allograft now available at Tissue Banks International

NicOx reports financial results for the first nine months of 2009

Electronic eye implant mimics human retina; restores partial vision

Gloomy health care statistics in Texas top state news

Lexicon Pharmaceuticals completes public offering of common stock shares

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

Mimetogen Pharmaceuticals completes its equity financing

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in